Software Engineer 1

Scale AI taps former Google Cloud executive as CEO. 30 Jul 2026 11:05PM Add CNA as a trusted source to help Google better understand and surface our content in search results. July 30 - Scale AI said on Thursday it had named former Google Cloud executive Francis DeSouza as chief executive officer, effective August 10, as the AI company looks to expand its data and applications businesses. DeSouza will succeed Jason Droege, who has served as interim CEO since June last year. Droege will work with deSouza in the coming months to support the transition, Scale said. Founded by Alexandr Wang, Scale provides data that powers frontier AI models and develops AI applications for businesses and governments. Last year, Wang joined Meta Platforms as its chief AI officer. Here are some details: - DeSouza has more than 30 years of experience in enterprise technology and most recently served as chief operating officer and president of security products at Google Cloud. - Before joining Google Cloud, DeSouza was president and CEO of Illumina, a genomic data and sequencing company. - Scale said that under DeSouza, Illumina's revenue grew to more than $4.5 billion and the company expanded into more than 150 countries. - Earlier in his career, he was president of products and services at cybersecurity company Symantec. He also founded two companies that were later acquired by Microsoft and Symantec. - DeSouza holds bachelor's and master's degrees in electrical engineering and computer science from the Massachusetts Institute of Technology. - Scale said it recently added BP and Mayo Clinic as enterprise customers and expanded its work with U.S. and international governments.

Juno Bio opens lab, raises $3.8 million to advance vaginal microbiome testing. 17-Jul-2026 Last updated on 17-Jul-2026 at 14:18 GMT According to Juno Bio, the new sequencing laboratory creates a stronger foundation for future research in areas including recurrent infections, co-infections, fertility-related vaginal microbiome patterns, and more. (@ Juno Bio) Juno Bio, known for its precision vaginal microbiome testing and multi-omics, has opened a sequencing laboratory in Oakland, California supported by funding from venture capital. Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator backed Juno Bio with $3.8 million to scale clinical infrastructure, which includes the first CLIA-certified sequencing laboratory focused on women's health. CLIA-certified laboratories meet rigorous federal quality standards. Juno Bio's laboratory will expand access to precision vaginal microbiome testing and provider-led care. "Bringing testing in-house gives us greater control over quality, speed, reliability and innovation," said Hana Janebdar, cofounder and CEO of Juno Bio. "This new lab allows us to move beyond a wellness test into a provider-led clinical platform, supporting physician ordering, clinical review, actionable results, and future R&D in gynecological health." According to the company, the new sequencing laboratory creates a stronger foundation for future research in areas including recurrent infections, co-infections, fertility-related vaginal microbiome patterns, peri- and menopausal symptoms, and broader microbiome patterns across different life stages. Explore related questions beta. Prior to the new facility, testing was conducted at a company laboratory and by third parties. 'Underfunded and under-researched' Juno Bio was first known for developing a wellness test that helped women understand their microbiome. The company has sold more than 20,000 of those kits. Juno Bio said the tests filled a need especially as company data showed over 67% of customers received incorrect vaginal diagnosis with other brand testing and only 13% had been successfully treated. While traditional tests focus on a limited set of pathogens, Juno Bio's platform can identify microbes associated with co-infections, subclinical conditions and broader microbiome patterns. The company recently launched its new vaginal microbiome and STI test that is processed in its CLIA-certified laboratory. The test analyzes about 10,000 bacteria and fungi, along with four common STIs, giving women a broader picture of the vaginal ecosystem. When paired with symptoms and clinician review, it can help clarify potential contributors to concerns such as bacterial vaginosis, yeast infections, aerobic vaginitis, cytolytic vaginosis and estrogen-related changes. Juno Bio has also evolved into a clinical platform which has allowed it to expand its scientific and clinical infrastructure through pharmaceutical R&D partnerships, telehealth and pharmacy integrations. The original wellness test is available in 46 states. "I think the bigger story is that we're building much more than a laboratory or a test," Janebdar said. "Our mission is to build the scientific and clinical infrastructure needed to transform how vaginal health conditions are understood, diagnosed, treated, and researched. Women's health, and vaginal health in particular, has historically been underfunded and under-researched." The company is working to change that by combining advanced sequencing, provider-led care, and ongoing research into a platform that can continue evolving over time. "While this funding, our new clinical test, and our CLIA-certified lab are important milestones, they're all part of a much larger vision to advance precision women's health and bring meaningful innovation to a category that has long been underserved," Janebdar said. Related topics. 07-Jul-2026 By Nikki Hancocks Higher consumption of ultra-processed food (UPF) correlates with poorer diet quality, higher sugar intake, lower mycobiome richness, and potentially altered cardiometabolic function, according to newly presented data. 24-Jun-2026 By Asia Sherman The Western diet is killing Nutraingredients, environmental contaminants are contributing to the disease burden, and its separation from the natural world has reduced its contact with the beneficial bacteria that once helped to protect Nutraingredients.

David P. King elected to Illumina's Board of Directors. PR Newswire Today at 1:15pm PDT Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ - Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. "We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders." Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies. Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting. About David P. King David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022-2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. About Illumina Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established Oregon Capital Insider as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with Oregon Capital Insider on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Illumina Investor Relations 858-291-6421 [email protected] SOURCE Illumina, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.